Merigan T - Search Results

1

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Eron JJ, et al. Among authors: merigan t. J Infect Dis. 2004 Mar 15;189(6):1075-83. doi: 10.1086/381707. Epub 2004 Mar 2. J Infect Dis. 2004. PMID: 14999611 Clinical Trial.

2

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Campbell TB, et al. Clin Infect Dis. 2005 Jul 15;41(2):236-42. doi: 10.1086/430709. Epub 2005 Jun 7. Clin Infect Dis. 2005. PMID: 15983922

3

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

Valentine FT, Kundu S, Haslett PA, Katzenstein D, Beckett L, Spino C, Borucki M, Vasquez M, Smith G, Korvick J, Kagan J, Merigan TC. Valentine FT, et al. Among authors: merigan tc. J Infect Dis. 1996 Jun;173(6):1336-46. doi: 10.1093/infdis/173.6.1336. J Infect Dis. 1996. PMID: 8648205 Clinical Trial.

4

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.

Schapiro JM, Lawrence J, Speck R, Winters MA, Efron B, Coombs RW, Collier AC, Merigan TC. Schapiro JM, et al. Among authors: merigan tc. J Infect Dis. 1999 Jan;179(1):249-53. doi: 10.1086/314541. J Infect Dis. 1999. PMID: 9841849 Clinical Trial.

5

Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.

Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. Lawrence J, et al. Among authors: merigan tc. J Infect Dis. 1999 Jun;179(6):1356-64. doi: 10.1086/314751. J Infect Dis. 1999. PMID: 10228055 Clinical Trial.

6

Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis.

Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC. Rasmussen L, et al. Among authors: merigan tc. J Infect Dis. 1994 Sep;170(3):673-7. doi: 10.1093/infdis/170.3.673. J Infect Dis. 1994. PMID: 7915750

7

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.

Kleim JP, Winters M, Dunkler A, Suarez JR, Riess G, Winkler I, Balzarini J, Oette D, Merigan TC. Kleim JP, et al. Among authors: merigan tc. J Infect Dis. 1999 Mar;179(3):709-13. doi: 10.1086/314633. J Infect Dis. 1999. PMID: 9952383 Clinical Trial.

8

A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.

Jellinger RM, Shafer RW, Merigan TC. Jellinger RM, et al. Among authors: merigan tc. J Infect Dis. 1997 Mar;175(3):561-6. doi: 10.1093/infdis/175.3.561. J Infect Dis. 1997. PMID: 9041326

9

Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.

Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC Jr, Glesby MJ; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Jacobson JM, et al. J Infect Dis. 2003 Dec 15;188(12):1804-14. doi: 10.1086/379899. Epub 2003 Dec 9. J Infect Dis. 2003. PMID: 14673758 Clinical Trial.

10

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients.

Rasmussen L, Hong C, Zipeto D, Morris S, Sherman D, Chou S, Miner R, Drew WL, Wolitz R, Dowling A, Warford A, Merigan TC. Rasmussen L, et al. Among authors: merigan tc. J Infect Dis. 1997 Jan;175(1):179-84. doi: 10.1093/infdis/175.1.179. J Infect Dis. 1997. PMID: 8985216

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

464 results

Search Page

Filters